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Abstract Caveolins (Cav-1, -2, and -3) are a gene family of
cytoplasmic membrane-anchored scaffolding proteins that: (i)
help to sculpt caveolae membranes from the plasma membrane
proper; and (ii) participate in the sequestration of inactive
signaling molecules. In the adult, caveolin-1 and -2 are co-
expressed and are most abundant in type I pneumocytes,
endothelia, fibroblastic cells and adipocytes, while the expression
of caveolin-3 is restricted to striated muscle cells. However, little
is known regarding the genomic organization and developmental
expression of the caveolin gene family. Here, using the mouse as
a model system, we examine the chromosomal localization, the
detailed intron-exon organization, and developmental expression
pattern of the caveolin gene family. cDNAs encoding caveolin-1,
-2, and -3 were used as probes to isolate murine genomic clones
containing these genes. Fluorescence in situ hybridization (FISH)
analysis using these genomic clones as probes reveals that all
three caveolin genes are localized to murine chromosome 6.
Specifically, caveolin-1 and -2 co-localize to chromosomal region
6-A2, while caveolin-3 is located within the chromosomal region
6-E1. Searches of the NCBI Human/Mouse Homology map
indicate that murine region 6-A2 corresponds to human
chromosome 7q31. As this region (6-A2/7q31) is the site of an
as yet unidentified tumor suppressor gene(s), our mapping studies
clearly define caveolin-1 and caveolin-2 as candidate genes that
may be deleted at these loci. All three caveolin genes show similar
intron-exon organization, with the last exon of each gene
encoding the bulk of the known caveolin functional domains.
The boundary position of the last exon is essentially identical in
all three caveolin genes, suggesting that they may have arisen
through gene duplication events. Developmentally, all three
caveolins were expressed late during mouse embryogenesis as
assessed by Northern and Western blot analysis. We examined
the localization of the caveolin proteins in sections of day 16
mouse embryos using a well-characterized panel of antibody
probes. Caveolin-1 and -2 were most abundantly expressed in the
developing lung parenchyma, while caveolin-3 was most abun-
dantly expressed in developing tissues that consist primarily of
skeletal muscle cells. As the expression of all three caveolins in
the adult is highest in terminally differentiated cell types, this is
consistent with the idea that caveolins may be viewed as late
markers of differentiation during embryogenesis.
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1. Introduction
Caveolae are 50^100-nm vesicular invaginations of the plas-
ma membrane [1]. It has been proposed that caveolae partic-
ipate in vesicular tra⁄cking events and signal transduction
processes [2^4]. Caveolin, a 21^24-kDa integral membrane
protein, is a principal component of caveolae membranes in
vivo [5^9].
Caveolin is only the ¢rst member of a new gene family; as a
consequence, caveolin has been re-termed caveolin-1 [10].
Caveolin-2 shows the same tissue distribution as caveolin-1
[11], while caveolin-3 is only expressed in striated muscle
cell types (cardiac and skeletal) [12^14]. It has been proposed
that caveolin family members function as sca¡olding proteins
[15] to organize and concentrate speci¢c lipids (cholesterol
and glycosphingolipids; [16^18]) and lipid-modi¢ed signaling
molecules (Src-like kinases, H-Ras, eNOS and G-proteins;
[16,19^23]) within caveolae membranes. In support of this
idea, caveolin-1 binding can functionally suppress the GTPase
activity of heterotrimeric G-proteins and inhibit the kinase
activity of Src-family tyrosine kinases, the EGF-receptor kin-
ase, and protein kinase C through a common caveolin do-
main, termed the caveolin-sca¡olding domain [19^21,24,25].
Thus, we have suggested that caveolin may function as a
negative regulator of many di¡erent classes of signaling mol-
ecules through the recognition of speci¢c caveolin-binding
motifs [4,26].
The direct interaction of caveolin with signaling molecules
leads to their inactivation [2^4]. Since many of these
signaling molecules can cause cellular transformation when
constitutively activated, it is reasonable to speculate that
caveolin itself may possess transformation suppressor activity.
Consistent with this hypothesis, both caveolae and caveolin
are most abundantly expressed in terminally di¡erentiated
cells : type I pneumocytes, endothelial cells, muscle cells,
and adipocytes [10,27^31]. In addition, caveolin-1 mRNA
and protein expression are lost or reduced during cell
transformation by activated oncogenes such as v-abl and
H-ras (G12V); caveolae are absent from these cell lines
[32].
The potential ‘transformation suppressor’ activity of caveo-
lin-1 has recently been evaluated by using an inducible expres-
sion system to up-regulate caveolin-1 expression in oncogeni-
cally transformed cells. Induction of caveolin-1 expression in
v-Abl- and H-Ras(G12V)-transformed NIH 3T3 cells abro-
gated the anchorage-independent growth of these cells in
soft agar and resulted in the de novo formation of caveolae
[33]. Thus, down-regulation of caveolin-1 expression and cav-
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eolae organelles may be critical to maintaining the trans-
formed phenotype.
In collaboration with Minetti and colleagues, we have
recently identi¢ed two di¡erent families in Italy with an
autosomal dominant form of limb girdle muscular dystrophy
that is due to a de¢ciency in caveolin-3 expression [34].
In these patients, by quantitative immuno£uorescence and
Western blot analysis, levels of the caveolin-3 protein
are reduced by s 95%. Analysis of their genomic DNA
reveals two distinct mutations: (i) a 9 base-pair micro-deletion
that removes the sequence TFT from the caveolin-sca¡olding
domain; and (ii) a mis-sense mutation that changes a proline
to a leucine (PCL) in the transmembrane domain [34].
As these mutations are heterozygous and show an auto-
somal dominant form of transmission, we must conclude
that these mutations cause the formation of a dominant-neg-
ative form of caveolin-3 [34]. As caveolin-1, -2, and -3 are
known to form both hetero- and homo-oligomers
[10,11,13,15,35], this may lead to the degradation of wild-
type caveolin-3.
Interestingly, comparison of the known protein sequences
of mammalian caveolin-1, -2, and -3 with Caenorhabditis ele-
gans caveolin-1 and -2, reveals that only 12 amino acid resi-
dues are invariant between worms and man [35]. These in-
clude two charged residues (R, D), ¢ve aromatic residues
(3F, W, Y), proline (2P), serine (2S), and glycine (G). Of these
12 invariant residues, two are a¡ected by the mutations iden-
ti¢ed in caveolin-3. One of the invariant prolines is changed to
leucine in Family A, while one of the invariant phenylalanines
is deleted in Family B [34]. These results suggest that mutation
of these evolutionarily conserved residues may have dire con-
sequences for the structure or functioning of the entire cav-
eolin gene family. In an independent report, we have previ-
ously shown that alanine scanning mutagenesis of a peptide
encoding the caveolin-sca¡olding domain reveals that the
FTVT/S sequence in caveolin-1 and -3 is important for the
correct recognition of caveolin-binding signaling molecules
[26]. Note that the FT portion of this FTVT/S sequence is
deleted in Family B. This ¢nding provides genetic evidence
that this region of the caveolin-sca¡olding domain is critical
in vivo.
Thus, mouse models of caveolin de¢ciencies will be impor-
tant for elucidating the potential role of caveolins in cancer-
ous cell transformation and in muscular dystrophy. However,
little is known regarding the genomic organization and devel-
opmental expression of the caveolin gene family in humans or
mice. Only the overall genomic structure of the chicken cav-
eolin-1 gene has been reported in detail [36].
Here, using the mouse as a model experimental system, we
examine the chromosomal localization, the detailed intron-
exon organization, and developmental expression pattern of
the caveolin gene family. More speci¢cally, we show that: (i)
all three caveolin genes are located on murine chromosome 6;
(ii) caveolin-1 and -2 co-localize to murine chromosomal re-
gion 6-A2; (iii) caveolin-3 is located within the murine chro-
mosomal region 6-E1; (iv) all three caveolin genes show sim-
ilar intron-exon organization, with the last exon of each gene
encoding the bulk of the known caveolin functional domains;
and (v) developmentally, all three caveolins were expressed
late during mouse embryogenesis as assessed by Northern
and Western blot analysis, but in a tissue-speci¢c fashion as
seen by immunocytochemistry.
2. Materials and methods
2.1. Materials
The cDNAs encoding caveolin-1, -2, and -3 were as we described
previously [10,13,37]. Antibodies and their sources were as follows:
anti-caveolin-1 IgG (mAb 2297; gift of Dr. John R. Glenney, Trans-
duction Labs); anti-caveolin-1 (pAb; rabbit anti-peptide antibody di-
rected against caveolin-1 residues 2^21; Santa Cruz Biotech, Inc.).
Mouse monoclonal antibodies directed against caveolin-2 (clone 65)
or caveolin-3 (clone 26) were as we described previously [11,12]. A
variety of other reagents were purchased commercially: fetal bovine
serum (FBS; JRH (Biosciences); pre-stained protein markers (Gibco-
BRL); Slow-Fade anti-fade reagent (Molecular Probes, Eugene, OR).
The mouse embryo Northern blot was purchased from Clontech, Inc.
Para⁄n sections containing day 16 mouse embryos were purchased
from Novagen, Inc. Whole mouse embryos were harvested on days 11
and 15 and used for Western blot analysis. Cy 3-conjugated donkey
anti-mouse and donkey anti-rabbit IgG were from Jackson Labora-
tories, Inc.
2.2. Isolation and characterization of genomic clones
Probes corresponding to the cDNAs of caveolin-1, -2, and -3 were
used to screen a previously described murine genomic library (for
caveolin-1; generous gift of H. Wu and R. Jaenisch, Whitehead In-
stitute) [38,39] or a mouse ES-129/SvJ II BAC library (for caveolin-2
and -3; Genome Systems, Inc.). To determine the genomic organiza-
tion of the caveolin genes, portions of these genomic inserts were
subcloned into the vector pBS-SK. The genomic organization of
each caveolin gene was then established by using Southern blotting
to develop a detailed restriction map of the region. The intron-exon
boundaries were established by dideoxy sequencing using speci¢c pri-
mers to the coding sequence of the caveolins.
2.3. Fluorescence in situ hybridization (FISH) analysis
Chromosomal localization of the murine caveolin gene family was
carried out in collaboration with Genome Systems. Brie£y, a given
mouse genomic clone was labeled with digoxigenin dUTP by nick
translation. The labeled probe was combined with sheared mouse
DNA and hybridized to normal metaphase chromosomes (derived
from mouse embryo ¢broblasts). Hybridization was carried out in a
solution containing 50% formamide, 10% dextran sulfate and 2USSC.
Hybridization signals were detected by incubating the hybridized
slides with FITC-labeled anti-digoxigenin IgGs. Chromosomes were
also counterstained with DAPI. Probes speci¢c for the centromeric
and telomeric region of chromosome 6 were used to con¢rm the local-
ization of the caveolin gene family. For each caveolin genomic clone,
a total of 80 metaphase cells were analyzed with 54, 74, and 71
showing speci¢c labeling for caveolin-1, -2, and -3, respectively.
2.4. Northern blot analysis
Hybridizations were performed in 50% formamide, 5USSC, 25 mM
Na-phosphate, pH 7.0, 10U Denhardts, 5 mM EDTA, 1% SDS,
0.1 mg/ml PolyA at 42‡C overnight and subsequently washed in
2USSC/0.1% SDS and 0.5USSC/0.1% SDS at 50‡C; radiolabeled
DNA concentrations were at 2U106 cpm/ml.
2.5. Western blot analysis
Mouse embryo extracts were prepared with IP bu¡er and homo-
genized on ice with a Polytron tissue grinder, as described [28]. Equal
amounts of protein (50 Wg) were loaded on an SDS-PAGE gel (12%
acrylamide) and transferred to nitrocellulose. After transfer, nitrocel-
lulose sheets were stained with Ponceau S to visualize protein bands
and subjected to immunoblotting. For immunoblotting, incubation
conditions were as described by the manufacturer (Amersham), except
we supplemented our blocking solution with both 1% BSA and 1%
non-fat dry milk (Carnation).
2.6. Immuno£uorescence microscopy
Para⁄n embedded sections were ¢rst cleared with xylene and rinsed
twice (2 min each) with 100% alcohol, 95% alcohol, and 80% alcohol.
(Note that alcohol for all washes is 90% ethanol/5% methanol/5%
isopropanol). Sections were then equilibrated with de-ionized water
for 5 min, followed by several rinses with fresh de-ionized water.
Slides were placed face-up in an incubation container and each section
was covered with a solution of 1% SDS in Tris-bu¡ered saline
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(100 mM Tris, pH 7.4, 138 mM NaCl, and 27 mM KCl). After 5 min,
slides were washed 3U with TBS (5 min each). To block non-speci¢c
binding, sections were incubated with a 1:10 dilution of horse serum
in TBS for 1 h at 37‡C. After blocking, sections were incubated with
antibodies directed against either caveolin-1, -2, or -3 for 2 h at 37‡C.
After rinsing with TBS (3U, 5 min each), sections were incubated
with Cy 3-conjugated donkey anti-mouse or donkey anti-rabbit IgG
(1:200 dilution in blocking bu¡er; Jackson Laboratories) for 1 h at
37‡C. Note that when the primary antibody used was a mouse mono-
clonal, the blocking solution also contained anti-mouse Fab fragments
(20 Wg/ml) to prevent the Cy 3-labeled secondary antibody from rec-
ognizing endogenous antibodies in the embryo sections. After rinsing
with TBS (3U, 5 min each), coverslips were mounted with Slow-Fade
anti-fade reagent and slides were examined by £uorescence micros-
copy using a Bio-Rad confocal microscope. Note that pre-treatment
of sections with 1% SDS has recently been shown to be an e¡ective
method for antigen retrieval, especially with anti-caveolin-1 IgG [40].
3. Results
3.1. Chromosomal localization and genomic organization of
murine caveolin gene family (Cav-1, Cav-2, and Cav-3)
The cDNAs encoding caveolin-1, -2, and -3 were used as
probes to isolate their corresponding genomic clones from a
murine genomic library. The clone numbers and the insert
sizes of these caveolin-containing genomic clones are summar-
ized in Table 1.
These genomic clones were next used as probes to deter-
mine the chromosomal localization of the caveolin gene fam-
ily by FISH analysis. Perhaps surprisingly, our results indicate
that all three caveolin genes are localized to murine chromo-
some 6. Caveolin-1 and -2 are co-localized to region 6-A2,
while the caveolin-3 gene is localized to region 6-E1 (Table 1).
To determine the genomic organization of the caveolin
genes, portions of these genomic inserts were subcloned. The
intron-exon boundaries were directly established by dideoxy
sequencing using speci¢c primers to the coding sequence of
the caveolins. The genomic organization of the genes encoding
caveolin-1, -2, and -3 is shown schematically in Fig. 1A. The
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Fig. 1. Genomic organization of the murine caveolin gene family. The relative sizes of exons and introns are as indicated and were determined
by direct sequencing and restriction mapping. A: Overall genomic organization of murine caveolin-1, -2, and -3. B: Speci¢c DNA sequences
surrounding various intron-exon boundaries.
Table 1
Chromosomal localization of murine caveolin-1, -2, and -3
Gene Clone # Insert size (kb) FISH analysis
Cav-1 3-2 V12-15 6 A2
Cav-2 17031 V80-120 6 A2
Cav-3 14316 V80-120 6 E1
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caveolin-1 gene contains 3 exons, while both caveolin-2 and
caveolin-3 genes contain only 2 exons. The corresponding
protein sequences encoded by each of these exons are sum-
marized in Table 2. Donor and acceptor splice junctions for
each exon are shown in Fig. 1B, and conform well to the
known consensus for these sites.
Interestingly, the boundary position of the last exon is es-
sentially identical in all three caveolin genes. An alignment of
the protein sequences encoded by this segment is shown in
Fig. 2. Note that most of the functional domains of the cav-
eolins are contained within this last exon, including the homo-
oligomerization domain, the sca¡olding domain, the mem-
brane spanning domain, and the C-terminal domain. In addi-
tion, this last exon encodes 10 of the 12 invariant residues that
are conserved from worms to man in all members of the
caveolin gene family. Mutations that involve these invariant
residues in human caveolin-3 have been identi¢ed in two dis-
tinct families with an autosomal dominant form of limb-girdle
muscular dystrophy [34].
Given that the murine caveolin gene family is (i) localized
to the same murine chromosome, and (ii) they share a similar
genomic organization with a virtually identical boundary for
the last exon, it is likely that the caveolin gene family arose
through gene duplication of this last exon.
3.2. Comparison with the organization of the caveolin gene
family in C. elegans
We compared the intron-exon organization of all three
murine caveolin genes with the known organization of a cav-
eolin gene from C. elegans, termed Cavce-1 ([35] ; Fig. 3, upper
panel). Interestingly, the position of the last exon in the
Cavce-1 gene corresponds well with the position of the last
exons of the murine caveolin gene family (compare Figs. 1
and 3).
The genomic organization of a second caveolin gene ex-
pressed in C. elegans (Cavce-2) was deduced here by compar-
ing the published cDNA sequence of Cavce-2 with the cosmid
C56A3 (accession number Z77655) and is shown in Fig. 3
(lower panel). Note that the Cavce-2 gene contains 10 exons
and does not generally resemble any of the murine caveolin
genes or the Cavce-1 gene in terms of its intron-exon organ-
ization. These ¢ndings suggest that the Cavce-2 may be an
ancestral predecessor of Cavce-1 and the mammalian caveolin
genes. Alternatively, the Cavce-2 gene may be the ¢rst member
of a new gene family of caveolins that have yet to be discov-
ered in mammals. In support of the latter notion, the genes
encoding Cavce-1 and Cavce-2 are located on di¡erent chro-
mosomes in C. elegans (chromosomes IV and V, respectively).
3.3. Developmental expression of murine caveolin-1, -2, and -3
in whole mouse embryos
In order to study the developmental expression of caveolins,
we performed Northern blot analysis on mRNA isolated from
mouse embryos (days 7, 11, 15 and 17). The expression of L-
actin mRNA was used as a control for equal loading. Our
results indicate that caveolin-1 and -2 show a biomodal pat-
tern of expression (Fig. 4A). mRNA species for both caveolin-
1 and -2 were expressed on day 7, down-regulated by day 11,
and upregulated by day 15, and remained elevated on day 17.
In contrast, caveolin-3 mRNA was ¢rst detectable on day 15
and remained elevated on day 17 (Fig. 4A).
To con¢rm the strong upregulation of caveolins between
days 11 and 15 at the protein level, we performed Western
blot analysis with isoform speci¢c antibody probes on extracts
prepared from embryos harvested on days 11 and 15. Fig. 4B
shows that on day 11, little or no protein expression of cav-
eolin-1, -2, and -3 was observed. However, in accordance with
our results from Northern blot analysis, all three caveolin
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Fig. 3. Genomic organization of the caveolin gene family in C. ele-
gans. The genomic organization of Cavce-1 was described previously
[35] and is reproduced here. The genomic organization of a second
caveolin gene expressed in C. elegans (Cavce-2) was deduced here by
comparing the published cDNA sequence of Cavce-2 [35] with the
cosmid C56A3 (accession number Z77655) and is shown. Note that
the Cavce-2 gene contains 10 exons and does not generally resemble
any of the murine caveolin genes or the Cavce-1 gene in terms of its
intron-exon organization. Interestingly, the position of the last exon
in the Cavce-1 gene corresponds well with the position of the last
exons of the murine caveolin gene family.
Fig. 2. Alignment of the protein sequences and functional domains
encoded by the last exon of the murine Cav-1, -2, and -3 genes.
The positions of the oligomerization domain (single overline), the
caveolin sca¡olding domain (double overline), the membrane span-
ning domain (boldface overline), and cysteines conserved in caveo-
lin-1 and -3 that are sites of palmitoylation (asterisks) are shown. In
addition, 10 of the 12 residues that are invariant between all known
mammalian caveolins and caveolins from C. elegans are localized to
this last exon and are boxed. Conserved residues that are deleted or
mutated in human caveolin-3 and lead to an autosomal dominant
form of limb-girdle muscular dystrophy [34] are indicated by a bold-
face underline.
Table 2
Genomic organization of the murine caveolin gene family
Gene Exon Size (bp) Protein segment encoded (aa)
Cav-1 1 30 1^10
2 165 11^65
3 342 66^178
Cav-2 1 150 1^50
2 339 51^162
Cav-3 1 114 1^38
2 342 39^151
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proteins were upregulated on day 15. Similarly, the protein
levels of all three caveolins also remained elevated on day 17
(not shown). These results further demonstrate that levels of
caveolin mRNA strictly correlate with protein expression, as
we have consistently observed previously in adult tissues and
cultured cells [10^13,28,32,41].
3.4. Localization of caveolin-1, -2 and -3 during development
As the mRNA and protein expression of all three caveolins
peaked on days 15^17, we next examined the localization of
caveolins in para⁄n embedded sections of day 16 mouse em-
bryos using a well-characterized panel of isoform speci¢c anti-
body probes.
Fig. 5A shows that both caveolin-1 and -2 proteins were
most abundantly expressed in lung parenchyma and also with-
in the epithelial cells that line the developing bronchioles. This
is in accordance with previous studies showing that both cav-
eolin-1 and -2 are abundantly expressed at the mRNA and
protein level in adult lung tissue. Interestingly, it has been
recently reported that caveolin-1 levels are down-regulated
in type I pneumocytes during lung ¢brosis, suggesting that
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Fig. 5. Immunolocalization of the caveolin gene family in day 16
mouse embryos. Para⁄n embedded sections of whole mouse em-
bryos were immunostained with a panel of isoform-speci¢c mono-
clonal and polyclonal antibodies that recognize either caveolin-1,
caveolin-2, or caveolin-3 selectively. A: Localization of caveolin-1
and -2 in lung parenchyma. B: Localization of caveolin-3 in tongue,
diaphragm, and skeletal muscle (from the hindlimb).
Fig. 4. Northern and Western blot analysis of the developmental ex-
pression of the murine caveolin gene family. A: Poly(A)-RNA
from day 7, 11, 15 and 17 mouse embryos was probed with the
cDNAs to caveolin-1, -2, and -3. L-Actin was used as a control for
equal loading. Note that caveolin-1 and -2 show a biomodal pattern
of expression. mRNA species for both caveolin-1 and -2 were ex-
pressed on day 7, down-regulated by day 11, and upregulated by
day 15, and remained upregulated on day 17. In contrast, caveolin-
3 mRNA was ¢rst detectable on day 15 and remained elevated on
day 17. B: Protein extracts were prepared from day 11 and 15
mouse embryos and probed by Western analysis using a panel of
well-characterized monoclonal antibodies speci¢c for either caveolin-
1, caveolin-2, or caveolin-3. Note that on day 11, little or no expres-
sion of caveolin-1, -2, and -3 was observed. However, in accordance
with our results from Northern blot analysis, all three caveolins
were upregulated on day 15. Each lane contains an equivalent
amount of protein extract (50 Wg) and this was con¢rmed by Pon-
ceau S staining prior to immunoblotting.
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caveolin-1 may be a negative marker for degenerative lung
disorders [42]. Conversely, our results here suggest that cav-
eolin-1 and -2 may be positive markers for lung maturation
during embryogenesis.
Fig. 5B shows that the caveolin-3 protein was most abun-
dantly expressed in the developing tongue, diaphragm, and
hindlimb muscle that consist primarily of skeletal muscle cells.
Similarly, in the adult, caveolin-3 expression is con¢ned pri-
marily to striated muscle cells (cardiac myocytes and skeletal
muscle ¢bers) [12^14]. Interestingly, little or no expression of
caveolin-3 was detected in developing cardiac muscle cells (not
shown); this is in striking contrast to the adult situation where
cardiac and skeletal muscle express equivalent amounts of
caveolin-3 [12^14]. However, as the expression of all three
caveolins in the adult is highest in terminally di¡erentiated
cell types [4], this is consistent with the idea that caveolins
may be viewed as late markers of di¡erentiation during em-
bryogenesis.
4. Discussion
In this study, we have determined that the genes encoding
murine caveolin-1 and caveolin-2 are co-localized within the
A2 region of mouse chromosome 6 (6-A2). Recently, the
genes encoding human caveolin-1 and -2 have been found to
map to the q31 region of human chromosome 7 (7q31; our
unpublished observations and [43]). In accordance with these
results, a search of the NCBI Human/Mouse Homology Map
reveals that the murine chromosomal region 6-A2 corresponds
precisely to the human chromosomal region 7q31.
There is now an accumulating body of evidence provided
by our lab and others that caveolin-1 mRNA and protein
expression is down-regulated during cell transformation of
cultured NIH 3T3 cells, in transgenic mouse models of breast
cancer, and in cell lines derived from human breast cancers
[32,33,44^46]. Furthermore, recombinant expression of caveo-
lin-1 in transformed NIH 3T3 cells or cell lines derived from
human breast cancers can suppress their transformed pheno-
type, such as anchorage-independent growth in soft agar
[33,46]. Interestingly, human chromosome 7q31 and murine
chromosome 6-A2 are often deleted or are translocational
break point sites in a wide variety of tumors. Such tumors
include hepatomas [47,48], ovarian cancers [49,50], prostate
cancers [51,52], uterine leiomyomas [53], myeloid neoplasms
[54], oral cancers [55], breast cancers [52], stomach adenocar-
cinomas [56], and renal cell carcinomas [57]. Based on these
studies it has been concluded that an as yet unidenti¢ed tumor
suppressor gene resides at 7q31/6-A2. Given that caveolin-1
possesses ‘transformation suppressor activity’ in vitro and
caveolin-1 and -2 are localized to this chromosomal region,
this unidenti¢ed tumor suppressor gene(s) may be caveolin-1
and/or -2. As many of these normal adult tissues express cav-
eolin-1 and -2, it will be important to determine whether any
of these chromosomal rearrangements leads to a loss of cav-
eolin mRNA or protein expression during tumorigenesis.
We have recently shown that mutations in the human cav-
eolin-3 gene, which maps to human chromosome 3p25, cause
an autosomal dominant form of limb-girdle muscular dystro-
phy [34]. Here, we show that murine caveolin-3 localizes to
chromosome 6-E1 in the mouse. A search of the NCBI Hu-
man/Mouse Homology Map indicates that these two regions
(human 3p25 and murine 6-E1) are also homologous. Thus,
the information provided here may help identify existing
mouse models of muscular dystrophy that are due to muta-
tions within the caveolin-3 gene. In addition, our studies
should aid e¡orts toward constructing ‘knock-out’ mice that
harbor homozygous targeted disruption of the caveolin genes.
Such future studies will allow us and others to develop whole
animal models to study the functional role of caveolins in
normal development and in pathogenic states, such as cancer
and muscular dystrophy.
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